Abstract: The present invention relates to a pharmaceutical composition containing a collagen-binding dimeric fusion protein comprising an extracellular domain of glycoprotein VI, the fusion protein having an amino acid sequence of SEQ ID NO: 1, or an amino acid sequence that is at least 99% homologous to the amino acid sequence of SEQ ID NO: 1 for use in the prevention or treatment of thrombotic complications in a patient suffering from an acute cardiovascular event, and fulfilling at least one of the following criteria (i) to (v): (i) a degree of carotid stenosis of at least 50% as defined by NASCET criteria or at least 70% as defined by ECST; (ii) no anti-platelet therapy prior to the acute cardiovascular event, (iii) revascularization procedures selected from carotid endarterectomy (CEA) or carotid angioplasty and stenting (CAS) and thrombolysis and thrombectomy via stent retriever are indicated; (iv) revascularization procedures selected from coronary angioplasty and stenting, and coronary artery bypass grafting (

Abstract: A pharmaceutical composition for parenteral application. comprising (a) more than 2.4 mg/ml of a collagen-binding dimeric fusion protein comprising an extracellular domain of glycoprotein VI, the fusion protein having an amino acid sequence of SEQ ID NO: 1, or an amino acid sequence that is at least 99% homologous to the amino acid sequence of SEQ ID NO: 1; and (b) a pharmaceutically acceptable buffer, the buffer comprising (b1) a buffering component in combination with a ph adjusting agent, which is 10 mM His/HCl, and (b2) 4 percent by weight of mannitol and (b3) 2.

Abstract: The present invention relates to a fusion protein selectively binding collagen and having ectonucleotidase activity. The fusion protein comprises an amino acid sequence of the extracellular domain of glycoprotein VI fused via a first linker sequence to the N-terminus of an amino acid sequence of an Fc region, whereby the C-terminus of the Fc region is linked via a second linker sequence to an amino acid sequence of the extracellular domain of a CD39 protein. The fusion protein is useful in the treatment or prevention of cardiovascular disease or diabetes, such as in the treatment of acute atherothrombotic events with a favorable risk-benefit ratio.

Abstract: The present invention relates to a fusion protein selectively binding collagen and having ectonucleotidase activity. The fusion protein comprises an amino acid sequence of the extracellular domain of glycoprotein VI fused via a first linker sequence to the N-terminus of an amino acid sequence of an Fc region, whereby the C-terminus of the Fc region is linked via a second linker sequence to an amino acid sequence of the extracellular domain of a CD39 protein. The fusion protein is useful in the treatment or prevention of cardiovascular disease or diabetes, such as in the treatment of acute atherothrombotic events with a favorable risk-benefit ratio.